AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NYSE:BIO.BBio-Rad Laboratories Stock Price, Forecast & News

$436.97
0.00 (0.00 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$436.97
Now: $436.97
$436.97
50-Day Range
$436.97
MA: $459.10
$475.29
52-Week Range
$307.28
Now: $436.97
$475.29
Volume200 shs
Average Volume250 shs
Market Capitalization$12.95 billion
P/E Ratio8.37
Dividend YieldN/A
Beta0.97
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:BIO.B
CUSIPN/A
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$7.12 per share
Book Value$192.32 per share

Profitability

Net Income$1.76 billion

Miscellaneous

Employees8,000
Market Cap$12.95 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive BIO.B News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.

Bio-Rad Laboratories (NYSE:BIO.B) Frequently Asked Questions

How has Bio-Rad Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Bio-Rad Laboratories' stock was trading at $350.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIO.B shares have increased by 24.8% and is now trading at $436.97. View which stocks have been most impacted by Coronavirus.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Bio-Rad Laboratories.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) released its quarterly earnings results on Wednesday, May, 6th. The company reported $1.91 EPS for the quarter. The firm earned $571.64 million during the quarter. Bio-Rad Laboratories had a net margin of 67.81% and a return on equity of 3.95%. View Bio-Rad Laboratories' earnings history.

Has Bio-Rad Laboratories been receiving favorable news coverage?

News stories about BIO.B stock have trended negative on Monday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Bio-Rad Laboratories.

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. VP & CFO (Age 60)
  • Mr. John Goetz, Consultant (Age 69)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO.B."

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO.B can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO.B stock can currently be purchased for approximately $436.97.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $12.95 billion and generates $2.31 billion in revenue each year. Bio-Rad Laboratories employs 8,000 workers across the globe.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DR, HERCULES CA, . The company can be reached via phone at 510-724-7000 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.